Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Narsoplimab in Paediatric High-Risk HSCT-Associated Thrombotic Microangiopathy
2021-002727-38Phase 2Active
- Sponsor
- Omeros Corporation
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of narsoplimab in thrombotic microangiopathies (TMA), sponsored by Omeros Corporation. Primary endpoint: 100-day survival rate. Started Oct 2022; status: active.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2021-002727-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002727-38.